The recent success of glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), has revolutionised the field of obesity treatment
Thyroid Tumors In animal studies, semaglutide was linked to thyroid tumors, though this has not been confirmed in humans
Overall, the transition is usually motivated by: Plateauing on semaglutide Interest in a dual GLP-1/GIP mechanism Provider-recommended adjustments A desire to explore alternative dosing structures Even with these benefits, switching requires careful planning, since the two medications differ significantly in potency and tolerability
commercial insurance often covers with prior authorization
And the phase-based approach that evolves as your body adapts to the medication